The FDA is clear­ly keep­ing up with the Kar­dashi­ans as its Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) raised con­cerns that Khloé Kar­dashi­an’s pro­mo­tion­al video for a Bio­haven Phar­ma­ceu­ti­cals mi­graine drug made false claims about quick re­lief in as lit­tle as 15 min­utes.

In re­al­i­ty, OPDP said in its first un­ti­tled let­ter of the year, clin­i­cal work to sup­port the drug, known as Nurtec ODT, be­gan mea­sur­ing how it works two hours af­ter dos­ing.

“Claims that Nurtec ODT pro­vides re­lief in 15-30 min­utes are not sup­port­ed by the clin­i­cal tri­al da­ta,” the FDA said in its let­ter re­leased Tues­day.

The video, which orig­i­nal­ly aired on ABC’s “The View” last sum­mer, al­so claims that Nurtec ODT is more ef­fec­tive than oth­er mi­graine drugs and a “gamechang­er.”

Again, the FDA makes clear that these com­par­a­tive claims are mis­lead­ing be­cause Bio­haven has not demon­strat­ed that Nurtec ODT is clin­i­cal­ly su­pe­ri­or to or more ef­fec­tive than oth­er pre­scrip­tion and over-the-counter drugs. The com­pa­ny has 15 work­ing days to re­spond to the FDA.

“Bio­haven is work­ing close­ly with the FDA to eval­u­ate their com­ments and re­spond,” the com­pa­ny said in an SEC fil­ing on Tues­day.

This isn’t the first run-in be­tween the FDA and the Kar­dashi­ans over their pro­mo­tion of drugs. Khloé’s sis­ter Kim pro­mot­ed Duch­es­nay’s morn­ing sick­ness drug Di­clegis on In­sta­gram back in 2015 and the FDA slammed the com­pa­ny with a warn­ing let­ter for not dis­clos­ing enough risk in­for­ma­tion in the post.

The FDA on Friday released about 10 million doses of J&J’s vaccine for use, and disposed of another 60 million doses that were manufactured at the now-shuttered Emergent BioSolutions facility in Baltimore where cross-contamination occurred.

The agency said it’s not yet ready to allow the Emergent plant to be included in the J&J EUA, but that may occur soon. FDA came to the decision to authorize some of the doses after reviewing facility records and quality testing results.

It appears that we have reached the end of the saga about the global insider trading ring that collectively reaped $100 million from placing “timely, profitable” trades in biotech stocks like Ariad, Pharmacyclics and Receptos.

Tomer Feingold and Dov Malnik — Israeli traders living in Switzerland — were the last out of eight to be charged as the SEC unraveled the scheme, which ran from 2013 through 2017. Together, according to a statement in March, the pair had pocketed more than $4 million.

Senate Finance Democrats took aim at Biogen’s pricey new Alzheimer’s drug on Thursday, but members on both sides of the aisle at a separate appropriations hearing didn’t question acting FDA commissioner Janet Woodcock on the approval.

“I was appalled that Biogen priced their Alzheimer’s drug approved by the FDA at $56,000 per year — I’m not going to debate whether this is effective or not, but it’s double the household median income for Michiganders over the age of 65,” Sen. Debbie Stabenow (D-MI) said at the finance hearing.